Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Sun S, Guo W, Wang Z, Wang X, Zhang G, Zhang H, et al. Development and validation of an immune-related prognostic signature in lung adenocarcinoma. Cancer Med. 2020;9:5960–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, et al. Lung cancer incidence in never smokers. J Clin Oncol. 2007;25:472–8.

Article  PubMed  Google Scholar 

Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5:288–300.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 2018;34:690.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horvath L, Thienpont B, Zhao L, Wolf D, Pircher A. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC)—novel approaches and future outlook. Mol Cancer. 2020;19:141.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boyero L, Sanchez-Gastaldo A, Alonso M, Noguera-Ucles JF, Molina-Pinelo S, Bernabe-Caro R. Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy. Cancers (Basel). 2020;12:3729.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, Li Z, Zhou K, Wang C, Jiang L, Zhang L, et al. Deciphering cell lineage specification of human lung adenocarcinoma with single-cell RNA sequencing. Nat Commun. 2021;12:6500.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Han X, Nie G. Responsive and activable nanomedicines for remodeling the tumor microenvironment. Nat Protoc. 2021;16:405–30.

Article  CAS  PubMed  Google Scholar 

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782–95.

Article  CAS  PubMed  Google Scholar 

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCloskey CW, Rodriguez GM, Galpin KJC, Vanderhyden BC. Ovarian cancer immunotherapy: preclinical models and emerging therapeutics. Cancers (Basel). 2018;10:244.

Article  PubMed  PubMed Central  Google Scholar 

Tekpli X, Lien T, Rossevold AH, Nebdal D, Borgen E, Ohnstad HO, et al. An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nat Commun. 2019;10:5499.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018;48(812–30):e14.

Google Scholar 

Song Z, Yang L, Zhou Z, Li P, Wang W, Cheng G, et al. Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis. Cell Death Dis. 2021;12:106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin BT, Chafin TK, Douglas MR, Douglas ME. ClineHelpR: an R package for genomic cline outlier detection and visualization. BMC Bioinfo. 2021;22:501.

Article  CAS  Google Scholar 

Liu W, Yuan K, Ye D. Reducing microarray data via nonnegative matrix factorization for visualization and clustering analysis. J Biomed Info. 2008;41:602–6.

Article  CAS  Google Scholar 

Khan P, Siddiqui JA, Lakshmanan I, Ganti AK, Salgia R, Jain M, et al. RNA-based therapies: a cog in the wheel of lung cancer defense. Mol Cancer. 2021;20:54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A. 2002;99:16899–903.

Article  PubMed  Google Scholar 

Poczobutt JM, De S, Yadav VK, Nguyen TT, Li H, Sippel TR, et al. Expression profiling of macrophages reveals multiple populations with distinct biological roles in an immunocompetent orthotopic model of lung cancer. J Immunol. 2016;196:2847–59.

Article  CAS  PubMed  Google Scholar 

Lin C, Liu A, Zhu J, Zhang X, Wu G, Ren P, et al. miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma. Nat Commun. 2014;5:4620.

Article  CAS  PubMed  Google Scholar 

Ooms LM, Binge LC, Davies EM, Rahman P, Conway JR, Gurung R, et al. The inositol polyphosphate 5-phosphatase PIPP regulates AKT1-dependent breast cancer growth and metastasis. Cancer Cell. 2015;28:155–69.

Article  CAS  PubMed  Google Scholar 

Fiermonte G, Paradies E, Todisco S, Marobbio CM, Palmieri F. A novel member of solute carrier family 25 (SLC25A42) is a transporter of coenzyme A and adenosine 3’,5’-diphosphate in human mitochondria. J Biol Chem. 2009;284:18152–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamuro J, Deguchi H, Fujita T, Ueda K, Tokuda Y, Hiramoto N, et al. Polarized expression of ion channels and solute carrier family transporters on heterogeneous cultured human corneal endothelial cells. Invest Ophthalmol Vis Sci. 2020;61:47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Porcelli V, Longo A, Palmieri L, Closs EI, Palmieri F. Asymmetric dimethylarginine is transported by the mitochondrial carrier SLC25A2. Amino Acids. 2016;48:427–36.

Article  CAS  PubMed  Google Scholar 

Chou FS, Wang PS. The SLC25A42 transcript is a biomarker for fetal reprogramming in response to placental insufficiency in preterm newborns under 32 weeks gestation-A pilot study. Front Pediatr. 2020;8:459.

Article  PubMed  PubMed Central  Google Scholar 

Zhao K, Li Z, Tian H. Twenty-gene-based prognostic model predicts lung adenocarcinoma survival. Onco Targets Ther. 2018;11:3415–24.

Article  PubMed  PubMed Central  Google Scholar 

Lin A, Yan WH. The emerging roles of human leukocyte antigen-F in immune modulation and viral infection. Front Immunol. 2019;10:964.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han S, Lee SY, Wang WW, Tan YB, Sim RHZ, Cheong R, et al. A perspective on cell therapy and cancer vaccine in biliary tract cancers (BTCs). Cancers (Basel). 2020;12:3404.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang X, Tang T, Zhang G, Liang T. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Mol Cancer. 2021;20:50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen T, Chen Z, Zhao ZJ, Wu J. Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer. Oncotarget. 2017;8:60975–86.

Article  PubMed  PubMed Central  Google Scholar 

Liu F, Wu H. CC chemokine receptors in lung adenocarcinoma: the inflammation-related prognostic biomarkers and immunotherapeutic targets. J Inflamm Res. 2021;14:267–85.

Article  PubMed  PubMed Central  Google Scholar 

Wu C, Li X, Zhang D, Xu B, Hu W, Zheng X, et al. IL-1beta-mediated up-regulation of WT1D via miR-144-3p and their synergistic effect with NF-kappaB/COX-2/HIF-1alpha pathway on cell proliferation in LUAD. Cell Physiol Biochem. 2018;48:2493–502.

Article  CAS  PubMed  Google Scholar 

Wang SS, Liu W, Ly D, Xu H, Qu L, Zhang L. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol. 2019;16:6–18.